DC
NBIX icon

Deere & Company’s Neurocrine Biosciences NBIX Stock Holding History

Deere & Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-45,577
Closed -$610K – 1034
2013
Q2 		$610K Buy
+45,577
New +$560K 0.04% 525

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Deere & Company's NBIX Position: Q3 2013 in Review

Deere & Company sold out of Neurocrine Biosciences (NBIX) in Q3 2013, closing a stake of 45,577 shares — an estimated $610K sold.

Deere & Company first reported a position in NBIX in Q2 2013 and held it in 1 quarter. The position peaked at $610K in Q2 2013. 122 funds tracked by Wall St. Rank hold NBIX as of Q3 2013.

  • Deere & Company reported no remaining Neurocrine Biosciences position as of Q3 2013 after selling out during the quarter.
  • Deere & Company sold 45,577 Neurocrine Biosciences shares in Q3 2013, an estimated $610K.
  • Deere & Company first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 1 quarter.
  • Deere & Company's Neurocrine Biosciences position peaked at $610K in Q2 2013.
  • 122 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2013.

Based on Deere & Company's 13F filing for Q3 2013, filed 12 Nov 2013.